Janux Therapeutics

20 articles with Janux Therapeutics

• Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

  3/10/2023

  Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

• Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference

  2/14/2023

  Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today announced that Janux management will participate in a Novel Immuno-Oncology (IO) panel discussion at Cowen's 43rd Annual Health Care Conference and be available for 1x1 meetings from March 6 to 8, 2023 in Boston.

• Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors

  12/27/2022

  Janux Therapeutics, Inc. announced that the Company has submitted the investigational new drug application for JANX008 to the U.S. Food and Drug Administration, an EGFR-TRACTr in development for the treatment of EGFR-expressing solid tumors, including non-small cell lung cancer, colorectal cancer, renal cell carcinoma, and squamous cell carcinoma of the head and neck.

• Janux Therapeutics to Present at Upcoming Investor Conferences in November

  11/22/2022

  Janux Therapeutics, Inc. today announced that Janux management will present at two upcoming investor conferences and be available for 1x1 meetings.

• Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

  11/10/2022

  Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the third quarter ended September 30, 2022, and provided a business update.

• Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer

  10/12/2022

  Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today announced the first patient has been dosed in a Phase 1 clinical trial of JANX007 in subjects with metastatic castration-resistant prostate cancer (mCRPC).

• Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources

  9/23/2022

  Janux Therapeutics, Inc., a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, announced the appointment of Brenda Van Vreeswyk as Head of Human Resources.

• Janux Therapeutics Appoints Winston Kung to Board of Directors

  9/22/2022

  Janux Therapeutics, Inc. announced the appointment of Winston Kung to the Company’s Board of Directors.

• Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September 2022

  8/31/2022

  Janux Therapeutics, Inc. announced that Janux management will participate and present at two upcoming investor conferences.

• Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

  8/9/2022

  Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the second quarter ended June 30, 2022, and provided a business update.

• Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference

  6/2/2022

  Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at the 2022 Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 11:00 a.m. ET in New York.

• Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer

  5/31/2022

  Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s investigational new drug (IND) application for its lead product candidate, JANX007.

• Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

  5/10/2022

  Janux Therapeutics, Inc., a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, reported financial results for the first quarter ended March 31, 2022 and provided a business update.

• 

  Pharma Expansions: Beigene, Boehringer Ingelheim to Break Ground for New Facilities

  4/29/2022

  Several biopharma companies are closing out the month of April with expansions to facilities, including a $3 billion investment to develop next-generation life science ecosystems.

• Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr

  4/26/2022

  Janux Therapeutics today announced its upcoming presentation of preclinical data for the Company’s two lead TRACTr programs, PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008).

• Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

  3/18/2022

  Janux Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.

• Janux Therapeutics to Present at Upcoming March Investor Conferences

  3/1/2022

  Janux Therapeutics, Inc. today announced that Janux management will participate in three upcoming investor conferences.

• Janux Therapeutics Appoints Byron Robinson, Ph.D., J.D., as Chief Strategy Officer

  3/1/2022

  Janux Therapeutics, Inc. today announced the appointment of Byron Robinson, Ph.D., J.D., as Chief Strategy Officer.

• Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference

  1/5/2022

  Janux Therapeutics, Inc. announced that Janux management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference being held January 10 to 13.

• Janux Therapeutics to Present Virtually at Upcoming Investor Conferences

  11/8/2021

  Janux Therapeutics, Inc. today announced that Janux management will participate in fireside chats at two upcoming virtual investor conferences: Cowen’s 5th Annual IO Next Summit